Anthony Brandimarto
Cardiovascular Disease · Philadelphia, PANPI 1962405936
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,277 of the $4,870 with a category attached, or 87.8%. It is spread thinly across 28 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,602 and has fallen 98.3% since, to $26 in 2023.
Across 314 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$826
- Pfizer$696
- Astellas Pharma US Inc$696
- Amgen$611
- Novartis$316
- Boston Scientific$284
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,27788%
- Education$59312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $826 |
| Pfizer | 70 | $696 |
| Astellas Pharma US Inc | 15 | $696 |
| Amgen | 36 | $611 |
| Novartis | 20 | $316 |
| Boston Scientific | 15 | $284 |
| Boehringer Ingelheim | 12 | $193 |
| Sanofi-aventis U.S. LLC | 11 | $169 |
| E.r. Squibb & Sons, L.L.C. | 14 | $158 |
| Abbott | 8 | $144 |
| Amarin Pharma, Inc. | 10 | $140 |
| AstraZeneca | 8 | $105 |
| Bayer | 5 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $63 |
| Regeneron Healthcare Solutions, Inc. | 4 | $61 |
| Akcea Therapeutics, Inc. | 2 | $40 |
| Merck | 2 | $35 |
| Edwards Lifesciences | 2 | $35 |
| Atricure, Inc. | 2 | $32 |
| Althera Pharmaceuticals LLC | 2 | $29 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Lemaitre Vascular, Inc. | 2 | $19 |
| Philips North America LLC | 1 | $19 |
| Altathera Pharmaceuticals LLC | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| GE HealthCare | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
How this compares
$4,870 in reported general payments places this provider in the 70th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.